Cardiovascular Systems (NASDAQ: CSII) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its competitors? We will compare Cardiovascular Systems to related businesses based on the strength of its analyst recommendations, earnings, valuation, profitability, institutional ownership, risk and dividends.
Earnings and Valuation
This table compares Cardiovascular Systems and its competitors revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cardiovascular Systems||$204.91 million||$5.43 million||-474.75|
|Cardiovascular Systems Competitors||$827.23 million||$159.49 million||36.26|
Cardiovascular Systems’ competitors have higher revenue and earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Cardiovascular Systems and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cardiovascular Systems Competitors||-127.07%||-36.30%||-10.21%|
Insider & Institutional Ownership
74.7% of Cardiovascular Systems shares are held by institutional investors. Comparatively, 63.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 3.3% of Cardiovascular Systems shares are held by company insiders. Comparatively, 13.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of recent recommendations for Cardiovascular Systems and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cardiovascular Systems Competitors||170||1121||2458||89||2.64|
Cardiovascular Systems currently has a consensus target price of $34.25, indicating a potential upside of 20.22%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 9.40%. Given Cardiovascular Systems’ higher probable upside, analysts plainly believe Cardiovascular Systems is more favorable than its competitors.
Volatility and Risk
Cardiovascular Systems has a beta of 2.54, suggesting that its stock price is 154% more volatile than the S&P 500. Comparatively, Cardiovascular Systems’ competitors have a beta of 1.06, suggesting that their average stock price is 6% more volatile than the S&P 500.
Cardiovascular Systems beats its competitors on 8 of the 13 factors compared.
About Cardiovascular Systems
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications. Its peripheral artery disease (PAD) systems are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee. Its products include Diamondback 360 Peripheral Orbital Atherectomy System (OAS) (Diamondback 360 Peripheral), the Stealth 360 OAS (Stealth 360), Diamondback 360 Peripheral, Diamondback 360 60cm Peripheral, Diamondback 360 Low Profile Peripheral, Diamondback 360 1.50 Peripheral and Diamondback 360 2.00 Peripheral. The Company’s coronary arterial disease (CAD) product, Diamondback 360 Coronary OAS (Coronary OAS), is marketed as a treatment for severely calcified coronary arteries.
What are top analysts saying about Cardiovascular Systems Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cardiovascular Systems Inc. and related companies.